Nature11 个月
Optimal first-line therapy for NSCLC with EGFR mutations
Activating mutations in EGFR are characteristic of patients with lung cancer who have high sensitivity to EGFR tyrosine kinase inhibitors, such as gefitinib and erlotinib. The randomized IPASS ...
Discovery of rapid COVID-19 replication mechanism could expand treatment options
Kim's team revealed that once COVID-19 invades human cells, it quickly modifies the structure and function ... that the virus ...